NCT01661881Active, not recruitingPhase 2
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
Mantle cell lymphoma (MCL) is not curable with conventional therapy. This study sought to improve upon standard of care in newly diagnosed, untreated MCL patients who were transplant-eligible using drugs already established as active in MCL. The combination of Rituximab-Bendamustine followed by Rituximab-Cytarabine (RB/RC) was expected to maximize pre-ASCT complete response (CR) rate compared to historical rates approximating 55% with tolerable toxicity.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 15 Jul 2012
- Start date
- 16 Aug 2012
- Primary completion date
- Feb 2015
- Lead sponsor
- Christine Ryan
- Diseases
- Mantle cell lymphoma
- NCT number
- NCT01661881
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 23
- From 16 Aug 2012 to the primary completion date, Feb 2015
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior anti-lymphoma therapy
- Receiving other study agents
Other illness
- Hypersensitivity to rituximab
- Uncontrolled intercurrent illness
- HIV positive on combination antiretroviral therapy
Other
- Pregnant or breastfeeding
Who the study is looking for
- Mandatory pathologic review of the diagnostic specimen(s) at Brigham and Women's Hospital or Massachusetts General Hospital
- Measurable disease
- Candidate for ASCT
Age in the registry: 18 years to 69 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.